Clinical Trial Update: Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

A phase 3 trial comparing dovitinib with sorafenib in metastatic renal cell carcinoma has completed, with results posted in November 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Dovitinib (dovitinib)
• Nexavar (Sorafenib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2015-11-06